Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?-Reference-Cited by-同舟云学术

Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?

Published:2015-06-24 Issue:7 Volume:87 Page:791-793
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Cocito Dario,Merola Aristide,Romagnolo Alberto,Peci Erdita,Toscano Antonio,Mazzeo Anna,Gentile Luca,Russo Massimo,Fazio Raffaella,Filosto Massimiliano,Siciliano Gabriele,Schirinzi Erica,Nobile-Orazio Eduardo,Lopiano Leonardo

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Surgery

Reference5 articles.

1. SCIg and Chronic Dysimmune Neuropathies Italian Network. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study;Cocito;J Neurol,2014

2. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies;Berger;Clin Immunol,2011

3. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects;Rajabally;J Neurol Neurosurg Psychiatry,2014

4. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy;Harbo;Neurology,2010

5. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy;Kuitwaard;J Neurol Neurosurg Psychiatry,2013

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis;Journal of Comparative Effectiveness Research;2024-09

2. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective;Journal of Clinical Medicine;2023-11-07

3. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States;PharmacoEconomics - Open;2023-02-09

4. Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders;Pharmaceuticals;2022-05-15

5. Immune Neuropathies;Acquired Neuromuscular Disorders;2022